AttgeNO

Executive Summary

AttgeNO AB is a Swedish clinical-stage pharmaceutical company founded in 2016, based on research from the Karolinska Institute. The company is developing novel nitric oxide (NO)-donating therapies, with its lead candidate, Supernitro, targeting acute pulmonary hypertension (aPH). Its technology aims to enable targeted, organ-specific delivery of nitric oxide for cardiovascular and pulmonary diseases. AttgeNO's approach addresses the high unmet need in aPH, where current therapies have limitations in efficacy and delivery. The company's platform could potentially be applied to other conditions, positioning it as a specialized player in the NO therapeutics space. As a private entity, AttgeNO has limited public disclosure, but its clinical-stage status suggests it has advanced beyond preclinical development. The company's success hinges on successful clinical trial outcomes and eventual regulatory approval. Given the early-stage nature and lack of disclosed funding or partnerships, the risk profile remains high. However, the differentiated technology and focus on a critical care indication provide a compelling investment thesis for those with risk tolerance. The company is headquartered in Uppsala, Sweden, and operates with a lean structure typical of small biotechs.

Upcoming Catalysts (preview)

• Q3 2026Completion of Phase 1 safety trial for Supernitro70% success
• Q4 2026Initiation of Phase 2 proof-of-concept study in acute pulmonary hypertension60% success